Amgen's low-ball offer to Onyx Pharmaceuticals has set off speculation of a potential bidding war that could leave another company walking away with Onyx.
Onyx Pharmaceuticals has rejected a $10 billion takeover bid from Amgen, reports CNBC's Bertha Coombs.
Fast Money trader Jon Najarian takes a look at some unusual activity in shares of Onyx Pharmaceuticals. And a play on the biotechnolgy space, with the FMHR crew.
Independent of the debate on the Federal Reserve and interest rates, FTI Consulting's Barbara Ryan expects pharmaceutical and biotech stocks can continue to do well.
The American Medical Association says obesity should be classified as a disease. CNBC's Bertha Coombs reports AMA's Patrice Harris says the hope is for doctors to be more proactive in treating obese patients.
Already sluggish health-care inflation is projected to slow down even more in 2014 as consumers, employers and the federal government continue looking to cut medical costs, a new report said Tuesday.
A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.
The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.
The FTC can challenge deals to keep generic drugs off the market, reports CNBC's Hampton Pearson.
Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.
Pfizer announced a $2.15 billion settlement from Teva Pharmaceuticals and and Sun Pharmaceutical for patent infringement on its drug Protonix.
Matthew Foy, partner, SR One and Peter Silvester, president of Life Technologies, discuss whether personalised medicine is a true disruptor or just for the rich.
GlaxoSmithKline fired the head of its R&D operations in China after a tipster spurred an inquiry that found "misrepresented" data were used in a multiple sclerosis study.
Obama administration to scrap age restrictions on the sale of morning-after pills, making the emergency contraception available to women and girls of any age without a prescription.
Can someone else patent your genes? The Supreme Court is scheduled to rule some time this month on that question. NBCNews.com reports.
AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion, as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
Forest Laboratories is trying to avert yet another bitter proxy battle with billionaire investor Carl Icahn ahead of its annual investor meeting this summer, sources said.
Joseph Jimenez, CEO of Novartis, says the pharmaceutical company is investing heavily to introduce new drugs in China as the spotlight shifts from infectious to chronic disease.
CNBC's Jackie DeAngelis reports which big pharma companies are leading in the fight against cancer.
Dr. Anthony Coles, Onyx Pharmaceuticals CEO & president, discusses promising results shown with liver cancer drug Nexavar, and reveals other new drugs coming to the market.